Shanghai Allist Pharmaceuticals (688578.SS)

Executive Summary

Shanghai Allist Pharmaceuticals is a Chinese biopharmaceutical company publicly traded on the Shanghai Stock Exchange (688578.SS) with a market valuation of approximately $5.9 billion. Founded in 2004, the company focuses on developing innovative drugs for cardiovascular, metabolic, and oncological indications. Allist has two commercial products and a pipeline that includes a Phase 2 trial evaluating furmonertinib in combination with anlotinib for non-small-cell lung cancer (NSCLC), as well as a preclinical TKI candidate for NSCLC. The company leverages its expertise in research, clinical development, and commercialization to address unmet medical needs in China and globally. With a strong balance sheet and a track record of bringing drugs to market, Allist is positioned for growth in the competitive biotech landscape, though its pipeline remains early-stage with limited near-term catalysts from later-stage trials.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 Data Readout for Furmonertinib + Anlotinib in NSCLC60% success
• Q4 2026Initiation of Phase 1/2 Trial for TKI Candidate in NSCLC70% success